Relative risk reduction versus number needed to treat as measures of lipid-lowering trial results

被引：7
|
作者：
Moriarty, PM [1 ]
机构：
[1] Univ Kansas, Med Ctr, Lipid Arteriosclerosis & Metab Clin, Kansas City, KS 66103 USA
来源：
AMERICAN JOURNAL OF CARDIOLOGY | 1998年 / 82卷 / 04期
关键词：
D O I：
10.1016/S0002-9149(98)00367-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Recent clinical trials dealing with cholesterol reduction in primary and secondary prevention for cardiovascular disease use Relative Risk Reduction to assess their clinical outcomes, Number Needed to Treat is a more valid measurement.
引用
收藏
页码：505 / +
页数：4
相关论文
共 50 条
  • [31] Metabolic and inflammatory risk reduction in response to lipid-lowering and lifestyle modification in the medically underserved individuals
    Chu, Michael P.
    Many, Gina
    Isquith, Daniel A.
    McKeeth, Susan
    Williamson, Jayne
    Neradilek, Moni B.
    Colletti, Patrick
    Zhao, Xue-Qiao
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 7
  • [32] Deriving number-needed-to-treat and number-needed-to-harm from the SAINT I trial results - Response to letter by Saver
    Koziol, James A.
    Feng, Anne C.
    STROKE, 2007, 38 (02) : 258 - 258
  • [33] Evidence-based dermatology: Number needed to treat and its relation to other risk measures
    Manriquez, Juan Jorge
    Villouta, Maria Francisca
    Williams, Hywel C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (04) : 664 - 671
  • [34] NUMBER NEEDED TO TREAT - RISK MEASURES EXPRESSED AS FREQUENCIES MAY HAVE A MORE RATIONAL RESPONSE
    AYTON, P
    BRITISH MEDICAL JOURNAL, 1995, 310 (6989): : 1269 - 1269
  • [35] Characteristics and Reporting of Number Needed to Treat, Number Needed to Harm, and Absolute Risk Reduction in Controlled Clinical Trials, 2001-2019
    Elliott, Marissa H.
    Skydel, Joshua J.
    Dhruva, Sanket S.
    Ross, Joseph S.
    Wallach, Joshua D.
    JAMA INTERNAL MEDICINE, 2021, 181 (02) : 282 - 284
  • [36] The effects of atorvastatin lipid-lowering therapy, in primary prevention of relative CHD risk in refugees and displaced persons with multifactorial risk
    Vulic, D
    Keric, L
    Vulic, B
    Pavic, Z
    Bajic, S
    ATHEROSCLEROSIS, 1999, 144 : 181 - 181
  • [37] Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial
    Raggi, P
    Callister, TQ
    Davidson, M
    Welty, FK
    Bachmann, GA
    Laskey, R
    Pittman, D
    Kafonek, S
    Scott, R
    AMERICAN HEART JOURNAL, 2001, 141 (05) : 722 - 726
  • [38] Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial
    Mitchell, LB
    Powell, JL
    Gillis, AM
    Kehl, V
    Hallstrom, AP
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (01) : 81 - 87
  • [39] A randomized comparison of patients’ understanding of number needed to treat and other common risk reduction formats
    Stacey L. Sheridan
    Michael P. Pignone
    Carmen L. Lewis
    Journal of General Internal Medicine, 2003, 18 : 884 - 892
  • [40] A randomized comparison of patients' understanding of number needed to treat and other common risk reduction formats
    Sheridan, SL
    Pignone, MP
    Lewis, CL
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2003, 18 (11) : 884 - 892
12345